|
Published by: SMI Publishing, Ltd
Published: Feb. 21, 2005
Table of Contents
- Day 1
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Cord Dohrmann, Chief Scientific Officer, DeveloGen.
- 9.10 TARGET IDENTIFICATION AND VALIDATION
- How should we validate targets for their ability to deliver anti-obesity drugs?
- Identifying the central targets for anti-obesity drugs - leptin vs others
- Current and novel targets
- Requirement of a successful drug for the treatment of obesity
- Challenges, benefits and limitations of these targets
- Dr Tung Fong, Director, Metabolic Disorders, Merck.
- 9.50 EARLY STAGE DISCOVERY
- Mechanisms and target choice
- Most promising targets: overview
- What about ghrelin?
- Dr Monique Berwaer, Principal Scientist/ Team Leader, Johnson & Johnson.
- 10.30 Morning Coffee
- 11.00 GUT PEPTIDES
- Do they signal hunger and satiety?
- The gut can signal to the brain via nerves or hormones
- Vagal nerve endings are sensitive to cholecystokinin, leptin and ghrelin
- The hormone ghrelin can induce feeding
- Systematically administered peptide YY can reduce food intake
- It has been hypothesised that the gut signals hunger and satiety to the brain
- Controversies concerning the actions of these peptides will be discussed
- Dr Simon Luckman, Pricipal Investigator & Senior Lecturer, University of Manchester.
- 11.40 PANEL DISCUSSION
- The role of ghrelin in regulating appetite - is the
- Dr Monique Berwaer, Principal Scientist/ Team Leader, Johnson & Johnson.
- Dr Simon Luckman, Pricipal Investigator & Senior Lecturer, University of Manchester.
- Dr Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals.
- 12.50 Networking Lunch
- 2.20 STIMULATION OF THERMOGENESIS AND OTHER INTERVENTIONS IN ENERGY METABOLISM
- Alternatives to centrally acting anorectic agents
- Why target metabolism?
- Overview of physiological and biochemical mechanisms
- Where and what are the targets?
- Validation of metabolic targets
- Expectations of thermogenic drugs
- Professor Jon Arch, Professorial Research Fellow & Deputy Director, Metabolic Research, University of Buckingham.
- 3.00 SYSTEMIC APPROACH TO IDENTIFY NOVEL GENES RELEVANT FOR THE TREATMENT OF OBESITY
- Phenotypic screening of mice treated with ENU for obesity relevant parameters
- High throughput in vivo screen with ENU mutagenesis
- Diseases vs therapy relevant genes for obesity
- Results will be exemplified by the Chagall phenotype
- Chagall mice have highly reduced adipose tissue and are resistant to high fat diet in the absence of gross metabolic changes
- This phenotype is caused by a point mutation in a novel transmembrane transporter
- Dr Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals.
- 4.00 OBESITY DRUGS
- Rationale for use and guidance for regulatory approval
- Obesity as a chronic disease and extent of the problem
- Rationale for use of obesity drugs, alone and in combination
- Discrimination against obesity: effects on obesity drug approval and use
- Characteristics and effectiveness of current obesity drugs
- Categories of future agents to treat obesity
- Elements of a successful clinical trial
- Current FDA guidances and potential modifications for future drugs
- Safety issues: balancing effectiveness and risks in using obesity drugs
- Dr Richard Atkinson, President, American Obesity Association.
- 4.40 SEROTONIN NOREPINEPHRINE RE-UPTAKE INHIBITOR
- Sibutramine
- Approval process
- Beneficial effects of Sibutramine on metabolic syndrome parameters
- Response in non-diabetic and diabetic patients
- Efficacy in long-term obesity management
- Dr Terry Opgenorth, Divisional Vice President, Metabolic Disease Research, Abbott Laboratories.
- 5.00 Chairman’s Closing Remarks and Close of Day One
- Day 2
- 8.30 Registration & Coffee
- 9.00 Chairman's Opening Remarks
- Dr Klaus Dembowsky, Vice President, Drug Discovery, Ingenium Pharmaceuticals.
- 9.10 GLOBAL MARKET OVERVIEW
- Insights into the obesity market
- Understanding the aetiology and epidemiologyof the obesity crisis
- The changing medical and popular perceptions of obesity
- Classification and designation of obesity as a disease
- Behaviour modification vs metabolic disorder: targeting school children and their families
- Profile of the target market and their future medical needs
- Obesity as underlying pathogenesis of diabetes and the metabolic syndrome
- Dr Manfred Ganz, Assessment Strategy & Business Development, Global Diabetes Care, F. Hoffmann-La Roche.
- 9.50 IN VIVO EFFICACY TESTING OF ANTI-OBESITY
- Diet induced obesity: rodent models (cafeteria diet, high-fat diet)
- Examples of the use of non-rodent species
- Sibutramine in Cynomolgus monkeys
- Dexfenfluramine in Rhesus monkeys
- Sibutramine in domestic pigs
- Dr Marcus Schindler, Associate Director & Group Leader, Metabolic Diseases, Boehringer-Ingelheim.
- 10.30 Morning Coffee
- 11.00 ATL-962: A NOVEL GASTROINTESTINAL LIPASE INHIBITORY ANTI-OBESITY DRUG
- Initial clinical development of ATL-962
- Pharmacodynamic studies
- Initial Phase IIb efficacy data from obese patients
- Positioning in anti-obesity pharmacotherapy
- Dr Richard Palmer, Executive Officer & Director, R & D, Alizyme.
- 11.40 INSULIN RESISTANCE AND ADIPOSE TISSUE
- Insulin resistance and T2D
- Adipose tissue as the primary site of insulin resistance?
- Screening for targets involved in the regulation of fat metabolism
- DG70 a novel kinase regulating insulin sensitivity
- Development of DG70 inhibitors as insulin sensitisers
- Dr Cord Dohrmann, Chief Scientific Officer, DeveloGen.
- 12.20 Networking Lunch
- 1.50 A DIET-INDUCED MARMOSET MODEL FOR OBESITY,
- Results will be presented on the development, validation and utility of a diet-induced obese Marmoset model that offers a predictive non-human primate model of obesity and metabolic syndrome
- Marmosets placed on a high-fat diet for three months exhibited a 27% increase in body weight
- Both body composition changes and serum chemistry modulations mirror those observed in obese humans
- Marmosets treated with the anti-obesity agents Rimonabant or Sibutramine for four weeks, demonstrated analogous changes in weight and serum chemistries as those achieved in the clinic
- In summary, diet-induced obese Marmosets are excellent models for the study of both obesity and metabolic syndrome that can ultimately be used to accelerate the development of pharmaceuticals to treat these rising epidemics
- Dr Mark Paulik, Group Leader, Metabolic Diseases, GlaxoSmithKline.
- 2.30 PGC-1: INSULIN RESISTANCE
- The association between insulin resistance
- Does obesity and physical inactivity aggravate insulin resistance?
- The symptoms of insulin resistance
- Causes of insulin resistance
- Treatment of insulin resistance
- Dr Richard Carr, Vice President, Discovery Management, Novo Nordisk, Library & Information Centre.
- Ms Karin Rimvall, Senior Scientist, Department Head, Novo Nordisk, Library & Information Centre.
- 3.10 Afternoon Tea
- 3.40 COMMON METABOLIC DISEASES: OBESITY AND TYPE 2 DIABETES
- New views on the progression from obesity to
- Aspects of the metabolic syndrome
- Understanding the physiological and biochemical factors underlying these metabolic disturbances
- New genes, new pathways and new endocrinology
- Discovering and validating potential new targets for obesity and diabetes
- Current approaches and novel drug targets
- Developing better therapeutic outcomes
- Dr Andrew Eisen, Assistant Director & Head, Metabolic Disorders, Cura Gen Corporation.
- 4.20 OBESITY-INDUCED HYPERTENSION
- The multifactorial and complex mechanisms
- The prevalence of obesity-related hypertension
- Adipocytokines and the pathogenesis of cardiovascular consequences of obesity
- Systemic hemodynamics in obesity
- Association of hyperinsulinema with obesity
- Studies and figures
- What this means for industry
- Clinical strategies
- Dr Yehonatan Sharabi, Head, Hypertension Unit, C. Sheba Medical Center.
- 5.00 Chairman’s Closing Remarks and Close of Day Two
AbstractNew opportunities in the treatment of obesity highlight significant commercial opportunities for the pharmaceutical industry today. The potential for anti-obesity treatment is extensive with an estimated clinically obese population of over 250 million globally in the year 2003. As a rapidly growing global epidemic, obesity is also a major factor for co-morbidities such as type II diabetes, cardiac disorders and hypertension, which now account for over 60% of the 56.5 million deaths per year around the world that are deemed preventable.
SMi’s 2nd Annual Conference on Obesity & Related Disorders will endeavour to review and evaluate the causes of obesity and associated chronic diseases, with a focus on the current and future opportunities in the anti-obesity drug market, disease management and product pipelines. This conference will also assess the success of anti-obesity drugs already released onto the market, current drivers and shapers and the future opportunities and novel mechanisms available to fight obesity.
Furthermore, SMi's Obesity & Related Disorders Conference will discuss the latest in regulatory guidelines, assessing both implication and implementation methods of achieving successful drug approvals.
A unique opportunity to learn from leading industry experts including:
- Dr Terry Opgenorth, Divisional Vice President, Metabolic Disease Research, Abbott
- Dr Tung Fong, Director, Metabolic Disorders, Merck
- Dr Richard Carr, Scientific Director, Experimental Medicine, Novo Nordisk
- Dr Monique Berwaer, Head, Metabolic Diseases, Johnson & Johnson
- Dr Manfred Ganz, Specialist Internal Medicine, Diabetologist & Associate Professor, Clinical Management, University of Rome & Director & Head, Medical Assessment Strategy & Business Development, Roche Diagnostics
- Dr Marcus Schindler, Associate Director & Group Leader, Metabolic Diseases, Boehringer-Ingelheim
- Dr Andrew Swick, Director, Cardiovascular & Metabolic Diseases, Pfizer
- Dr Yehonatan Sharabi, Head, Hypertension Unit, C. Sheba Medical Center & Investigator, National Institute of Neurological Disorders & Stroke (NINDS), National Institutes of Health
Get Full Details About This Report >>
|
|
US: 800.298.5699
Int'l: +1.240.747.3093
|
|
|
